Synapse - Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma

Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma Journal Article

Authors:	McBride, S.; Sherman, E.; Tsai, C. J.; Baxi, S.; Aghalar, J.; Eng, J.; Zhi, W. I.; McFarland, D.; Michel, L. S.; Young, R.; Lefkowitz, R.; Spielsinger, D.; Zhang, Z.; Flynn, J.; Dunn, L.; Ho, A.; Riaz, N.; Pfister, D.; Lee, N.
Article Title:	Randomized phase II trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma
Abstract:	PURPOSE The objective response rate (ORR) for single-agent anti-programmed death receptor 1 (anti-PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). We aimed to test whether radiotherapy may act synergistically with anti-PD-1 therapy to improve response through the abscopal effect. PATIENTS AND METHODS We conducted a single-center, randomized, phase II trial of nivolumab (anti-PD-1 therapy) versus nivolumab plus stereotactic body radiotherapy (SBRT) in patients with metastatic HNSCC. Patients had at least two metastatic lesions: one that could be safely irradiated and one measurable by RECIST version 1.1. Patients were randomly assigned (1:1), stratified by human papillomavirus status, to nivolumab (3 mg/kg intravenously every 2 weeks) or nivolumab (same dose) plus SBRT (9 Gy x 3) to 1 lesion. The primary end point was ORR in nonirradiated lesions, which was assessed by RECIST in patients with at least one available set of on-treatment images; safety was assessed in a per-protocol population. RESULTS Between March 11, 2016, and June 22, 2018, 62 patients were randomly assigned to nivolumab (n = 30) or nivolumab plus SBRT (n = 32). There was no statistically significant ORR difference between arms (34.5% [95% CI, 19.9% to 52.7%] v 29.0% [95% CI, 16.1% to 46.6%]; P = .86). There was no significant difference in overall survival (P = .75), progression-free survival (P = .79), or response duration (P = .26). Grade 3-5 toxicities were similar (13.3% v 9.7%; P = .70). CONCLUSION We found no improvement in response and no evidence of an abscopal effect with the addition of SBRT to nivolumab in unselected patients with metastatic HNSCC.
Keywords:	recurrent; pembrolizumab
Journal Title:	Journal of Clinical Oncology
Volume:	39
Issue:	1
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2021-01-01
Start Page:	30
End Page:	37
Language:	English
ACCESSION:	WOS:000611172100006
DOI:	10.1200/jco.20.00290
PROVIDER:	wos
PUBMED:	32822275
PMCID:	PMC8462641
Notes:	Article -- Source: Wos